SELLAS Life Sciences Group Inc. (SLS): Rasio rega marang pendapatan
The price-to-sales ratio provided by GURU.Markets correlates with the business's dependence on the success of leukemia therapy, and 41.00 determines the current value of this metric for SELLAS Life Sciences (SLS). The strategy is based on developing peptide vaccines to combat tumors. Currently, SELLAS Life Sciences (SLS) is fully focused on the clinical trials of its pipeline, excluding any merger or acquisition deals.
SELLAS Life Sciences (SLS) - rincian metrik lan laporan keuangan
- kuotasi saiki lan rata-rata prakiraan nilai:
- data kapitalisasi bursa:
- statistik nilai buku emiten:
- indikator beban kredit lan likuiditas emiten:
Koefisien Total Utang marang Modal SELLAS Life Sciences|SLS - Rasio utang jangka dawa marang ekuitas|Rasio tanggungan utang jangka cendhak marang modal sellaslifesciences.com|SLS - Utang perusahaan|Rasio utang marang kapitalisasi buku SELLAS Life Sciences Group Inc.|SLS - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak SELLAS Life Sciences|Rasio likuiditas kritis sellaslifesciences.com
- rincian asil keuangan lan kelipatan valuasi:
SLS - Bathi resik|Bathi resik sing dikarepake SELLAS Life Sciences|SLS - Koefisien rega marang bathi|Pangali mangsa ngarep rega marang bathi sellaslifesciences.com|SLS - Rasio rega marang bathi tumrap wutah|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan SELLAS Life Sciences Group Inc.|SLS - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan SELLAS Life Sciences|SLS - Bathi resik saben saham (EPS TTM)|Owah-owahan bathi resik saben saham taun-ka-taun sajrone rolas wulan pungkasan sellaslifesciences.com|SLS - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep SELLAS Life Sciences
- rincian pendapatan lan dodolan emiten:
Analisis fundamental perusahaan:SELLAS Life Sciences Group, Inc. SLS
The robotization of peptide synthesis and data analysis automation at SELLAS Life Sciences (SLS) are transforming the operational efficiency of oncology drug development, turning the technology stack into a core asset. By analyzing the company's historical P/S ratio, an investor determines the market value of a single dollar of revenue, which makes it possible to identify an overpayment for future growth rates or detect hidden capital accumulation by institutional investors.
Perusahaan pesaing
ONC - Rega marang dodolan|Rasio rega marang pendapatan Halozyme HALO|Revolution Medicines Inc - Rasio rega marang pendapatan|AAPG - Rasio rega marang pendapatan|CGON: Rasio rega marang pendapatan|URGN: Multiplikator P/S|bicara.com (BCAX) - Multiplikator P/S|Rasio rega marang pendapatan Personalis|Erasca Inc (ERAS) - Koefisien rega marang pendapatan|Kapitalisasi marang pendapatan DCTH (Delcath)|YMAB (Y-mAbs Corp) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Aura Biosciences, Inc. AURA|Candel Therapeutics Inc. - Rasio rega marang pendapatan|Accuray - Multiplikator P/S|Koefisien rega marang pendapatan Actuate Therapeutics Inc. ACTU|CTOR: Multiplikator P/S|Rasio rega marang dodolan HURA (TuHURA Biosciences)|TARA (Protara Therapeutics) - Multiplikator P/S|Rega marang dodolan fatetherapeutics.com FATE|Kapitalisasi marang pendapatan WHWK (Aadi Bioscience Inc)|TCRX (tscan.com) - Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Champions Oncology, Inc. CSBR|Koefisien rega marang pendapatan XBiotech Inc (XBIT)|CEL-SCI Corp - Multiplikator P/S|ostherapies.com (OSTX) - Kapitalisasi marang pendapatan|RADX: Multiplikator P/S|ARTV - Koefisien rega marang pendapatan|ANL (Adlai Nortye Ltd) - Multiplikator P/S|Rega marang dodolan Veru Corporation VERU|Rasio rega marang pendapatan Tempest Therapeutics (TPST)|xiliotx.com - Rasio kapitalisasi marang pendapatan|Multiplikator P/S RENB (Renovaro)|MURA - Kapitalisasi marang pendapatan|Kairos Pharma Inc - Multiplikator P/S|Rega marang dodolan OnKure Therapeutics Inc|w2.cytomed.sg (GDTC) - Rasio rega marang pendapatan|CRIS - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Apollomics Inc.|Tharimmune Inc (THAR) - Koefisien rega marang pendapatan|Rasio rega marang pendapatan Advanced Biomed Inc (ADVB)|Rasio rega marang pendapatan GNPX (Genprex Inc)|Rasio rega marang pendapatan Calidi Biotherapeutics, Inc. CLDI|Koefisien rega marang pendapatan sunshinebiopharma.com (SBFM)|Xenetic Bio - Multiplikator P/S|Salarius Pharmaceuticals Inc (SLRX) - Kapitalisasi marang pendapatan|PPBT: Multiplikator P/S|American Oncology Network, Inc. (AONC) - Multiplikator P/S|Rasio rega marang pendapatan BeiGene, Ltd.|Rasio kapitalisasi marang pendapatan CKPT (checkpointtx.com)|Multiplikator P/S ELEV|Kapitalisasi marang pendapatan icadmed.com ICAD|Multiplikator P/S IKNA (Ikena Oncology)|Notable Labs Corp (NTBL) - Rega marang dodolan|VIRX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan MOR (morphosys.com)|NAYA (NAYA Biosciences Inc.) - Kapitalisasi marang pendapatan|Ascentage Pharma Group International - Rasio kapitalisasi pasar marang pendapatan
